Short answer
Steris (STE) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). New $1.6B revolving facility replaces existing agreement, with maturity extended to November 4, 2031.
Steris 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- New $1.6B revolving facility replaces existing agreement, with maturity extended to November 4, 2031
- Revolver supports liquidity, letters of credit and swingline borrowings, with potential $800M commitment expansion
- Up to $500M delayed-draw term loan specifically tied to the Xodus Medical acquisition
- Term loan matures five years after acquisition closing, with no principal amortization during year one
- Financing adds acquisition capacity while remaining subject to leverage and minimum interest-coverage covenants
Item 1.02 · Termination of a Material Definitive Agreement
- Existing Revolving Credit Agreement termination disclosed through Item 1.01 cross-reference
- Investors should review Item 1.01 for replacement financing terms and potential liquidity implications
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 links to Item 1.01, indicating a material agreement created a direct financial obligation
- Investors should review Item 1.01 for the obligation’s amount, terms, maturity and business purpose
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Steris 8-K filings
Get the next STE 8-K as it lands
Follow STE for push alerts, or ask the research agent what this filing means.